10-Q: Nutra Pharma Q1 2026 Financial Results Analysis

Nutra Pharma Corp. reports a net loss of $459,675 for Q1 2026, citing ongoing liquidity challenges and significant debt defaults.

Summary

• Net loss for the three months ended March 31, 2026, was $459,675, compared to a loss of $1,404,923 in the same period of 2025.
• Net sales decreased to $48,214 in Q1 2026 from $110,394 in Q1 2025.
• The company maintains a working capital deficit of $17,243,345 and an accumulated deficit of $78,738,204.
• Management reports substantial doubt regarding the company's ability to continue as a going concern.
• The company raised $235,200 from convertible notes and $83,250 from promissory notes during the quarter.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to the persistent going concern warning, massive accumulated deficit, and reliance on dilutive debt financing.

Positives

• Net loss significantly narrowed by 67.28% compared to the prior-year period.
• Recognized a $140,500 gain on debt settlement during the first quarter of 2026.
• Expanded online marketing efforts for Nyloxin and Pet Pain-Away, including placement on Chewy.com.

Negatives

• Net sales declined by approximately 56% year-over-year.
• Significant indebtedness remains in default, with $5,387,529 of notes currently in default and under negotiation.
• The company's common stock is relegated to the OTC Expert Market, limiting capital-raising capabilities.
• Operating expenses remain high relative to revenue, with payroll and professional fees totaling $287,788 for the quarter.

Risks

• Substantial doubt regarding the ability to continue as a going concern due to recurring losses and working capital deficits.
• Insufficient cash to sustain operations for the next twelve months without additional financing.
• Potential for substantial dilution to existing shareholders if equity capital is raised to fund operations.
• Ongoing legal and regulatory risks, including the impact of the SEC final judgment requiring $680,235 in payments.
• Dependence on a single related party (Avini Health) for 43% of total revenues.

Future Outlook

The company plans to continue marketing efforts for its pain relief products, re-engage in regulatory approval processes for Canada in 2026, and initiate Phase I/II trials for RPI78M in late 2026, contingent upon securing adequate financing.

Management Comments

• Management acknowledges that current sales are not adequate to fund operations and the company relies on debt and equity funding.
• Management believes the company requires approximately $1,200,000 to fund existing operations over the next twelve months.

Industry Context

StockSavvy.ai notes that Nutra Pharma operates in a highly speculative niche of the biotechnology sector, struggling with legacy debt and regulatory scrutiny that significantly hampers its ability to compete with established pharmaceutical or consumer health companies.

Comparison to Industry Standards

• The company's reliance on debt financing and high default rates are significantly worse than industry standards for viable biotech firms.
• The lack of institutional support and relegation to the OTC Expert Market indicates a distressed financial position compared to publicly traded peers.

Corporate Governance

Legal Proceedings

• SEC v. Nutra Pharma Corporation et al.: Final judgment issued in July 2024 requiring $680,235 in payments.
• CSA 8411, LLC v. Nutra Pharma Corp.: Resolved via settlement in May 2025; all payments completed by February 2026.
• Marc Weller v. Nutra Pharma Corporation: Resolved via settlement in January 2026.

Related Party Transactions

• Sales to Avini Health accounted for 43% of total revenues in Q1 2026.
• The company operates rent-free in a facility leased by Avini Health.
• Significant accrued payroll and debt obligations are owed to officers and directors.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises.
• Creditors are impacted by the company's ongoing default on multiple promissory notes.
• Employees and consultants are dependent on the company's ability to secure new funding.

Next Steps

• Secure additional financing to fund operations for the next 12 months.
• Continue negotiations to settle outstanding debt in default.
• Re-engage in regulatory approval processes for Canadian market entry.
• Initiate Phase I/II clinical trials for RPI78M in late 2026.

Key Dates

Recommendation

The company is in a distressed financial state with substantial doubt regarding its ability to continue as a going concern, significant debt defaults, and a history of regulatory issues, making it an extremely high-risk investment.

Keywords

Nutra Pharma, Biotechnology, Homeopathic, Nyloxin, OTC, Debt Default, Going Concern, SEC Filing